Bonacini M, Lin H J, Hollinger F B
Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA.
J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):340-4. doi: 10.1097/00126334-200104010-00008.
To evaluate the diagnostic accuracy of the test for antibodies to hepatitis C virus by enzyme-linked immunosorbent assay (anti-HCV ELISA-2) in patients with and without HIV-1 infection.
Cohort study.
In all, 369 patients were tested and grouped by available serologic tests. HCV RNA was quantified in these 369 patients using an Amplicor HCV (and/or HIV-1) Monitor, v1.0 test. Among 110 patients who were anti-HCV negative by ELISA-2, 39 were HIV/HBV coinfected and 71 had HIV alone. One hundred twelve patients were HIV/HCV coinfected and 147 patients had HCV infection alone.
Six of 110 (5.5%) ELISA-2 anti-HCV-negative, HIV-infected patients had circulating serum HCV RNA. Their median CD4 count was 36 cells/mm(3), which was significantly lower than that observed in the HIV/HBV group (median CD4 = 109, p <.001) or the HIV/HCV cohort (CD4 = 235; p <.0001). The positive predictive value of the ELISA-2 test for diagnosing ongoing HCV infection in HIV-infected patients was 91%, which is significantly better than that determined for the HCV group, 76% (p =.002) presumably because HCV is less likely to resolve in the HIV patients. Mean alanine aminotransferase (ALT) levels were similar in the HIV/HCV (133 IU/L) and HCV (130 IU/L) cohorts. Median HCV RNA levels were higher in the HIV/HCV group (6.53 log(10) copies/ml) compared with the patients with HCV infection (5.62 log(10) copies/ml; p <.00001). There was no significant correlation between HCV RNA levels and ALT values, CD4 counts, or HIV RNA concentrations.
The predictive value of the anti-HCV ELISA-2 test is better in HIV-coinfected patients than in patients infected only with HCV. False negative results, usually associated with acute infection or with low CD4 counts, are uncommon. These patients may be diagnosed with the ELISA-3 assay or by reverse transcriptase polymerase chain reaction (RT-PCR). Compared with patients with only HCV infection, HIV/HCV patients display similar ALT profiles, but a higher proportion of detectable serum HCV RNA.
评估酶联免疫吸附试验(抗-HCV ELISA-2)检测丙型肝炎病毒抗体在合并或未合并HIV-1感染患者中的诊断准确性。
队列研究。
共检测369例患者,并根据现有血清学检测结果进行分组。使用Amplicor HCV(和/或HIV-1)监测仪v1.0检测对这369例患者的HCV RNA进行定量分析。在ELISA-2检测抗-HCV阴性的110例患者中,39例为HIV/HBV合并感染,71例仅感染HIV。112例患者为HIV/HCV合并感染,147例患者仅感染HCV。
110例ELISA-2抗-HCV阴性的HIV感染患者中有6例(5.5%)循环血清中存在HCV RNA。他们的CD4细胞计数中位数为36个/立方毫米,显著低于HIV/HBV组(CD4中位数 = 109,p <.001)或HIV/HCV队列(CD4 = 235;p <.0001)。ELISA-2检测在诊断HIV感染患者中正在进行的HCV感染时的阳性预测值为91%,显著高于HCV组的76%(p =.002),可能是因为HCV在HIV患者中更不易清除。HIV/HCV组(133 IU/L)和HCV组(130 IU/L)的平均丙氨酸氨基转移酶(ALT)水平相似。与HCV感染患者相比,HIV/HCV组的HCV RNA水平中位数更高(6.53 log₁₀拷贝/毫升)(5.62 log₁₀拷贝/毫升;p <.00001)。HCV RNA水平与ALT值、CD4细胞计数或HIV RNA浓度之间无显著相关性。
抗-HCV ELISA-2检测在合并HIV感染的患者中的预测价值优于仅感染HCV的患者。通常与急性感染或CD4细胞计数低相关的假阴性结果并不常见。这些患者可通过ELISA-3检测或逆转录聚合酶链反应(RT-PCR)进行诊断。与仅感染HCV的患者相比,HIV/HCV患者的ALT水平相似,但可检测到血清HCV RNA的比例更高。